<?xml version='1.0' encoding='utf-8'?>
<document id="26813987"><sentence text="Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report."><entity charOffset="56-65" id="DDI-PubMed.26813987.s1.e0" text="ibrutinib" /><entity charOffset="70-79" id="DDI-PubMed.26813987.s1.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26813987.s1.e0" e2="DDI-PubMed.26813987.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26813987.s1.e0" e2="DDI-PubMed.26813987.s1.e1" /></sentence><sentence text="Ibrutinib is a recently approved oral anticancer agent with pharmacokinetics that is very sensitive to metabolic inhibition"><entity charOffset="0-9" id="DDI-PubMed.26813987.s2.e0" text="Ibrutinib" /></sentence><sentence text=" We report a serious side effect of ibrutinib potentially attributable to interaction with the moderate CYP3A4 inhibitor verapamil"><entity charOffset="36-45" id="DDI-PubMed.26813987.s3.e0" text="ibrutinib" /></sentence><sentence text="" /><sentence text="A patient with mantle cell lymphoma was admitted to our emergency department with severe diarrhoea" /><sentence text=" During a prescription review, the clinical pharmacist identified a potential drug interaction between ibrutinib and verapamil present in a branded combination product also containing trandolapril"><entity charOffset="103-112" id="DDI-PubMed.26813987.s6.e0" text="ibrutinib" /><entity charOffset="117-126" id="DDI-PubMed.26813987.s6.e1" text="verapamil" /><entity charOffset="184-196" id="DDI-PubMed.26813987.s6.e2" text="trandolapril" /><pair ddi="false" e1="DDI-PubMed.26813987.s6.e0" e2="DDI-PubMed.26813987.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26813987.s6.e0" e2="DDI-PubMed.26813987.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26813987.s6.e0" e2="DDI-PubMed.26813987.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26813987.s6.e1" e2="DDI-PubMed.26813987.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26813987.s6.e1" e2="DDI-PubMed.26813987.s6.e2" /></sentence><sentence text=" Ibrutinib was discontinued for 5 days, and verapamil was stopped"><entity charOffset="1-10" id="DDI-PubMed.26813987.s7.e0" text="Ibrutinib" /><entity charOffset="44-53" id="DDI-PubMed.26813987.s7.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26813987.s7.e0" e2="DDI-PubMed.26813987.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26813987.s7.e0" e2="DDI-PubMed.26813987.s7.e1" /></sentence><sentence text=" Lercanidipine 10 mg daily was prescribed as an alternative antihypertensive drug"><entity charOffset="1-14" id="DDI-PubMed.26813987.s8.e0" text="Lercanidipine" /></sentence><sentence text=" The patient was discharged after 3 days with symptomatic treatment for his diarrhoea" /><sentence text=" Three months later, the patient maintained control with ibrutinib and olmesartan, but without verapamil"><entity charOffset="57-66" id="DDI-PubMed.26813987.s10.e0" text="ibrutinib" /><entity charOffset="71-81" id="DDI-PubMed.26813987.s10.e1" text="olmesartan" /><entity charOffset="95-104" id="DDI-PubMed.26813987.s10.e2" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.26813987.s10.e0" e2="DDI-PubMed.26813987.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26813987.s10.e0" e2="DDI-PubMed.26813987.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26813987.s10.e0" e2="DDI-PubMed.26813987.s10.e2" /><pair ddi="false" e1="DDI-PubMed.26813987.s10.e1" e2="DDI-PubMed.26813987.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26813987.s10.e1" e2="DDI-PubMed.26813987.s10.e2" /></sentence><sentence text="" /><sentence text="This is the first description of a serious side effect of ibrutinib likely due to an interaction with the CYP3A4 inhibitor verapamil"><entity charOffset="58-67" id="DDI-PubMed.26813987.s12.e0" text="ibrutinib" /></sentence><sentence text=" Prescriptions of ibrutinib must be carefully checked to identify possible interactions with CYP3A4 inhibitors and patients monitored accordingly"><entity charOffset="18-27" id="DDI-PubMed.26813987.s13.e0" text="ibrutinib" /></sentence><sentence text="" /></document>